614 related articles for article (PubMed ID: 34074295)
1. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer.
Nagasaka M; Uddin MH; Al-Hallak MN; Rahman S; Balasubramanian S; Sukari A; Azmi AS
Mol Cancer; 2021 Jun; 20(1):82. PubMed ID: 34074295
[TBL] [Abstract][Full Text] [Related]
2. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
3. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
4. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.
Oh Y; Yoon SM; Lee J; Park JH; Lee S; Hong T; Chung LI; Sudhaman S; Riddell T; Palsuledesai CC; Krainock M; Liu MC; Chae YK
Thorac Cancer; 2024 May; 15(13):1095-1102. PubMed ID: 38558374
[TBL] [Abstract][Full Text] [Related]
5. The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future.
Scilla KA; Rolfo C
Curr Treat Options Oncol; 2019 Jun; 20(7):61. PubMed ID: 31203467
[TBL] [Abstract][Full Text] [Related]
6. Evaluating circulating cell-free DNA and DNA integrity index as biomarkers in non-small cell lung cancer.
Ezzeldin N; El-Lebedy D; Hassan M; Shalaby AO; Hussein SAM; Gharib AM; Hamdy G; Mohammed AM; Ramadan A; Sobeih ME
J Egypt Natl Canc Inst; 2024 Jun; 36(1):21. PubMed ID: 38880832
[TBL] [Abstract][Full Text] [Related]
7. Single tube liquid biopsy for advanced non-small cell lung cancer.
de Wit S; Rossi E; Weber S; Tamminga M; Manicone M; Swennenhuis JF; Groothuis-Oudshoorn CGM; Vidotto R; Facchinetti A; Zeune LL; Schuuring E; Zamarchi R; Hiltermann TJN; Speicher MR; Heitzer E; Terstappen LWMM; Groen HJM
Int J Cancer; 2019 Jun; 144(12):3127-3137. PubMed ID: 30536653
[TBL] [Abstract][Full Text] [Related]
8. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.
Waldeck S; Mitschke J; Wiesemann S; Rassner M; Andrieux G; Deuter M; Mutter J; Lüchtenborg AM; Kottmann D; Titze L; Zeisel C; Jolic M; Philipp U; Lassmann S; Bronsert P; Greil C; Rawluk J; Becker H; Isbell L; Müller A; Doostkam S; Passlick B; Börries M; Duyster J; Wehrle J; Scherer F; von Bubnoff N
Mol Oncol; 2022 Jan; 16(2):527-537. PubMed ID: 34653314
[TBL] [Abstract][Full Text] [Related]
9. Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer.
Pellini B; Szymanski J; Chin RI; Jones PA; Chaudhuri AA
Thorac Surg Clin; 2020 May; 30(2):165-177. PubMed ID: 32327175
[TBL] [Abstract][Full Text] [Related]
10. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.
Abbosh C; Frankell AM; Harrison T; Kisistok J; Garnett A; Johnson L; Veeriah S; Moreau M; Chesh A; Chaunzwa TL; Weiss J; Schroeder MR; Ward S; Grigoriadis K; Shahpurwalla A; Litchfield K; Puttick C; Biswas D; Karasaki T; Black JRM; Martínez-Ruiz C; Bakir MA; Pich O; Watkins TBK; Lim EL; Huebner A; Moore DA; Godin-Heymann N; L'Hernault A; Bye H; Odell A; Roberts P; Gomes F; Patel AJ; Manzano E; Hiley CT; Carey N; Riley J; Cook DE; Hodgson D; Stetson D; Barrett JC; Kortlever RM; Evan GI; Hackshaw A; Daber RD; Shaw JA; Aerts HJWL; Licon A; Stahl J; Jamal-Hanjani M; ; Birkbak NJ; McGranahan N; Swanton C
Nature; 2023 Apr; 616(7957):553-562. PubMed ID: 37055640
[TBL] [Abstract][Full Text] [Related]
11. Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages.
Guibert N; Pradines A; Favre G; Mazieres J
Eur Respir Rev; 2020 Mar; 29(155):. PubMed ID: 32051167
[TBL] [Abstract][Full Text] [Related]
12. Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer.
Shen H; Jin Y; Zhao H; Wu M; Zhang K; Wei Z; Wang X; Wang Z; Li Y; Yang F; Wang J; Chen K
BMC Med; 2022 Dec; 20(1):480. PubMed ID: 36514063
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancer.
Bossé Y; Dasgupta A; Abadier M; Guthrie V; Song F; Saavedra Armero V; Gaudreault N; Orain M; Lamaze FC; Melton C; Nance T; Hung T; Hodgson D; Abbosh C; Joubert P
Cancer Lett; 2024 Jul; 594():216984. PubMed ID: 38797230
[TBL] [Abstract][Full Text] [Related]
14. Tumor-educated platelet as liquid biopsy in lung cancer patients.
Liu L; Lin F; Ma X; Chen Z; Yu J
Crit Rev Oncol Hematol; 2020 Feb; 146():102863. PubMed ID: 31935617
[TBL] [Abstract][Full Text] [Related]
15. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
[TBL] [Abstract][Full Text] [Related]
16. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY
Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939
[TBL] [Abstract][Full Text] [Related]
17. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
18. Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
Pi C; Zhang MF; Peng XX; Zhang YC; Xu CR; Zhou Q
Expert Rev Mol Diagn; 2017 Dec; 17(12):1089-1096. PubMed ID: 29057681
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R
Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340
[TBL] [Abstract][Full Text] [Related]
20. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
